PMID: 9419445Jan 7, 1998Paper

p53-based immunotherapy of cancer

Critical Reviews in Immunology
A B DeLeo

Abstract

Immunotherapy targeting p53 missense mutations, which occur in nearly half of all human tumors, is limited by several factors, including the constraints of antigen processing and presentation. Due to the accumulation of mutated p53 molecules in tumors expressing p53 mutations, an alternative approach would be to target wild-type sequence, CTL-defined p53 epitopes. Obviously, the possibility of an autoimmune response is a major potential drawback to this therapy. Immunization of BALB/c mice with bone marrow-derived dendritic cells (DC) generated in the presence of GM-CSF/IL-4 and prepulsed with the H-2Kd-binding wild-type p53(232-240) peptide has been shown to induce anti-peptide CTL. These effectors were cross-reactive against sarcomas expressing p53 missense mutations outside of the p53(232-240) epitope, but not within it. Mitogen-activated splenocytes, which express elevated levels of p53, were not sensitive to these CTL. The p53 peptide-pulsed DC-based vaccine was shown to be effective in inducing tumor rejection in immunization and therapy models in the absence of any observable deleterious effect on naive mice. The murine model has now been extended to include the use of genetically modified DC-based vaccines as well.

Citations

Apr 20, 2004·Cancer Immunology, Immunotherapy : CII·Thomas K HoffmannTheresa L Whiteside
Apr 2, 2008·Current Oncology Reports·Michael S LeibowitzRobert L Ferris
Mar 29, 2012·Immunologic Research·Charles C L TongAndrew G Sikora
May 14, 2010·Cold Spring Harbor Perspectives in Biology·David P LaneSonia Lain
Oct 12, 2010·Clinical & Developmental Immunology·Joel F AldrichRonald C Kennedy
Jul 19, 2011·Journal of Biomedicine & Biotechnology·Kazufumi Suzuki, Hisahiro Matsubara
Jul 19, 2002·International Journal of Cancer. Journal International Du Cancer·Pia BjörckWalter J Storkus
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Peter A Würtzen, Mogens H Claesson
Oct 30, 2004·International Journal of Cancer. Journal International Du Cancer·Vito R CicinnatiAlbert B DeLeo
Apr 24, 2012·Surgical Oncology·Mallika TewariHari S Shukla
Feb 5, 2002·Annual Review of Physiology·Sabine Zochbauer-MullerJohn D Minna
Mar 23, 2004·Annual Review of Immunology·Yun-Cai Liu
Jan 26, 2005·ORL; Journal for Oto-rhino-laryngology and Its Related Specialties·Robert L Ferris
Jul 14, 2000·Journal of Hematotherapy & Stem Cell Research·J Barrett, R Childs
May 29, 2009·Journal of Experimental & Clinical Cancer Research : CR·Aldo Venuti
Oct 27, 2010·Nature Reviews. Clinical Oncology·Chit Fang CheokDavid P Lane
Jul 10, 2019·Journal of Molecular Cell Biology·Robert A Weinberg
May 18, 2020·International Journal of Molecular Sciences·Arjelle Decasa AgupitanYgal Haupt
Jan 14, 2012·Expert Opinion on Therapeutic Targets·Alexander H Stegh
Nov 15, 2012·Current Opinion in Oncology·Daniel MenendezMichael A Resnick
May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·E V FedoseyevaG Benichou
Nov 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·T K HoffmannA B DeLeo
Jan 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Thomas K HoffmannAlbert B DeLeo
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Takayoshi MurakamiToshiyoshi Fujiwara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.